Financial Hits Keep Coming

Quote

Ouch!

Guest
Tough news on mandatory price cuts in Japan, 15% to 25% on Lixiana which is more than 30% of gross revenue for FY “20. This is crushing and takes effect 4/1. LIX is our top selling drug by a lot. This one will hurt
 












It’s real. It came from Pharma Japan and is mandatory in Japan, it’s a “large seller” tax and Keytruda got hit with it too and leads to 15 to 25 price decline but maybe they planned for this
 






It’s early - but looking at 50% reduction in US, most of ONC going to AZ and several internal functions being eliminated and will be run by AZ, so far I’ve heard sales training and more to come tomorrow
 






























But you have that awesome oncology pipeline. And do you really think those at the top care. Like John G and Greg B in the past they make money regardless. Only the ones mining the tunnel care. They don’t care about you. Get it thru your head
 






anonymous said:
But you have that awesome oncology pipeline. And do you really think those at the top care. Like John G and Greg B in the past they make money regardless. Only the ones mining the tunnel care. They don’t care about you. Get it thru your head
Click to expand...

I don’t think they care, 8201 will be obsolete in 6 to 9 months and we have people leading in oncology who never worked in oncology other than Simon how does that make sense?
 






Finance has already been tasked with modeling scenarios for a downsize by end of year, revenue loss for EDO is too significant to not make changes. Sorry all, but it’s coming
 










































Top Bottom
Back
Quote